Cantor Fitzgerald analyst Bryan Brokmeier believes the FDA's decision to halt blood donations in two Florida counties could accelerate adoption of Cerus' INTERCEPT-treated plasma. Cerus offers the only FDA approved pathogen inactivation technology, Brokmeier tells investors in a research note. The FDA's recommendation may cause blood centers to accelerate their planned adoption of INTERCEPT for platelets, the analyst contends. He estimates that an outbreak in Zika may pull forward $26.2M of plasma revenue and $29.7M of platelet revenue into 2017, or sooner. Brokmeier keeps a Buy rating on Cerus with a $9 price target.